Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FluMist Initial Indication May Exclude Patients Under Age Five

Executive Summary

The initial label for MedImmune/Wyeth's intranasal influenza vaccine FluMist might not include an indication for children under age five
Advertisement

Related Content

FluMist 60,000-Patient Phase IV Safety Study To Be Conducted With Kaiser
FluMist 60,000-Patient Phase IV Safety Study To Be Conducted With Kaiser
FluMist Pharmacy Administration In 36 States Upon Approval – MedImmune
FluMist Comparison To Inactivated Vaccine Suggested By FDA Committee
MedImmune FluMist review
Flumist advisory committee
From The Quarterly Conference Calls
Medimmune FluMist Indication Could Exclude Patients With Asthma
Kaiser FluMist Safety Data Analysis To Be Submitted To FDA By Year-End
Wyeth/Aviron FluMist Pulmonary Safety Requires More Analysis - FDA Cmte.
Advertisement
UsernamePublicRestriction

Register

PS040725

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel